Tradition Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Tradition Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$197K	Sell	53,657 -14,081	-21%	-$46.9K	0.01%	509
2026 Q1	$208K	Buy	67,738 +1,325	+2%	+$5.12K	0.01%	470
2025 Q4	$272K	Buy	66,413 +25,702	+63%	+$127K	0.02%	404
2025 Q3	$199K	Buy	+40,711	New	+$214K	0.01%	459
2024 Q1	–	Sell	-1,584	Closed	-$16K	–	1020
2023 Q4	$16K	Buy	1,584 +500	+46%	+$3.56K	﹤0.01%	902
2023 Q3	$8K	Buy	+1,084	New	+$10.8K	﹤0.01%	1071

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tradition Wealth Management's RXRX Position: Q2 2026 in Review

Tradition Wealth Management reduced its Recursion Pharmaceuticals (RXRX) stake by 21% in Q2 2026, selling an estimated $46.9K and leaving 53,657 shares worth $197K. The position accounts for 0.01% of the portfolio, ranked #509.

Tradition Wealth Management first reported a position in RXRX in Q3 2023 and has held it in 6 quarters since. The position peaked at $272K in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Tradition Wealth Management held 53,657 shares of Recursion Pharmaceuticals worth $197K as of Q2 2026.
Tradition Wealth Management sold 14,081 Recursion Pharmaceuticals shares in Q2 2026, an estimated $46.9K.
Recursion Pharmaceuticals made up 0.01% of Tradition Wealth Management's portfolio in Q2 2026, its #509 holding.
Tradition Wealth Management first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 6 quarters since.
Tradition Wealth Management's Recursion Pharmaceuticals position peaked at $272K in Q4 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Tradition Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.